Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

FinvizFinviz2026/02/24 12:33
By:Finviz

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center 

Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival

SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).

The Phase 1/2a clinical trial is a dose escalation and expansion trial of 177Lu-BetaBart, designed to evaluate its safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with its preliminary anti-tumor activity. The trial will also determine the recommended dose of 177Lu-BetaBart for future studies. This agent was developed by Radiopharm Ventures, a joint venture between Radiopharm and The University of Texas MD Anderson Cancer Center.

177Lu-Betabart is a Lu

177
-tagged engineered monoclonal antibody, designed with a strong affinity for the 4Ig isoform of B7-H3. B7-H3 is an immune checkpoint molecule that is overexpressed across several tumor types and has emerged as a compelling target for antibody-based cancer immunotherapy.

“Dosing of the first patient in the Phase 1/2a trial of 177Lu-BetaBart marks an important milestone for Radiopharm, as this is the first radiotherapeutic agent from our joint venture to enter the clinic,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “177Lu-BetaBart has the potential to become a highly differentiated radiotherapeutic for patients with aggressive advanced solid tumors, and we are grateful to our collaborators and participants in this Phase 1/2a trial.”

"We are honored to administer the first dose of 177Lu-BetaBart in this Phase 1/2a clinical trial,” noted Brandon Mancini, MD, MBA, FACRO, Medical Director at BAMF Health. “As a leading center for radiopharmaceutical therapeutic trials, we appreciate the opportunity to provide this novel, first-in-class radiotherapeutic for the treatment of a variety of advanced refractory solid tumors, while offering exceptional care to our clinical trial participants.”

In preclinical studies, 177Lu-BetaBart has shown evidence of efficacy and targeting of the specific 4Ig isoform of B7-H3, supporting its potential use in multiple indications, including prostate, pancreatic, breast and other solid tumors.

About RV-01
RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. RV-01 is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with RV-01 have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent.

About the Phase 1/2a Clinical Trial
The FIH Phase 1/2a study (NCT07189871) is designed to establish the safety profile, biodistribution, pharmacokinetics, and radiation dosimetry of 177Lu-Betabart (RV-01). The study aims to enroll 61 eligible participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal squamous cell carcinoma.

About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

How much are AI "mind-decoding" startups worth? OpenAI once offered $5 billion

According to The Information, OpenAI once offered over $5 billion to acquire the startup Goodfire, which is about four times its $1.25 billion Series B valuation. Founded in 2024, Goodfire focuses on decoding AI "thought processes." The negotiations ultimately broke down because Goodfire believes that remaining independent and providing technology to multiple AI companies will bring long-term value far exceeding $5 billion.

华尔街见闻•2026/11/17 02:56
How much are AI "mind-decoding" startups worth? OpenAI once offered $5 billion

Morgan Stanley 2027 Macroeconomic Outlook: AI Boom Faces "Big Test" from Oil Prices, Federal Reserve Interest Rate Hikes May Peak in Q1

The current core contradiction in the macroeconomy lies in the game between "AI-driven growth" and "persistent inflation triggered by oil prices."

智通财经•2026/11/17 02:37
Morgan Stanley 2027 Macroeconomic Outlook: AI Boom Faces "Big Test" from Oil Prices, Federal Reserve Interest Rate Hikes May Peak in Q1

Huang Renxun’s resignation causes turmoil: “AI central bank” tightens, New Cloud companies face financing risks

With Jensen Huang stepping down, the AI infrastructure financing ecosystem faces systemic restructuring risks. CoreWeave dropped more than 8% on Monday, with unsecured bond yields approaching distress levels; Nebius once fell nearly 10%. Data center operators are simultaneously tightening lease terms for junk-rated clients, investment-grade credit spreads are widening, and hyperscale data center CDS has returned to above 450 basis points.

华尔街见闻•2026/11/17 02:26